Navigation Links
Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
Date:4/1/2011

BALTIMORE, Md., April 1, 2011 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC: CSBR) ("Champions" or "the Company") announced today that it has exercised an option to license Irinophore C™, a liposomal formulation of Irinotecan, from the BC Cancer Agency ("BCCA") in British Columbia, Canada. This action was the result of the positive results obtained from a Tumorgraft™ study done on Irinophore C™ utilizing Champions' proprietary technology platform.

Irinophore C™ is a lipid-based nanoparticle made by efficiently loading the irinotecan payload into its interior core using a novel and proprietary method. The compound is currently completing preclinical development and is due to enter phase I clinical study as a single agent in patients having advanced solid tumors in Q4 2011.  Champions tested the activity of Irinophore C™ using its Tumorgraft™ translational technology platform.  The results demonstrated significant efficacy and safety advantages in Irinophore C™ as compared to the approved drug Irinotecan (Camptosar) on various tumor types.

In February 2010, Champions entered into an exclusive option agreement with BCCA for the exclusive right to review Irinophore C™ for the treatment of various forms of solid tumor cancer. The exercise of the option will result in immediate costs to the Company of approximately $85,000 comprised of the option exercise price and reimbursement to BCCA for past patent costs. Champions is currently exploring strategic options for financing the clinical development costs of Irinophore C™.

The Company also announced that it will not pursue further any of the three compounds for which it signed licensing agreements. The Company's scientific advisory committee has reviewed the results of the Tumorgraft™ studies performed on each of these compounds and recommended that the Company stop investing resources in the development of these compoun
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Champions CFO Resigns
2. Champions Biotechnology Awarded $1.46 million in Grants
3. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
4. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
5. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
6. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
7. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
8. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
9. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
10. Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
11. Pharma ChemOutsourcing Targets BioNJ, PA Bio, MassBio, BayBio, SoCalBio, and NY Biotechnology Association Member Companies for September 2011 Show in New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014   Royal Philips ... announced it has received 510(k) clearance from the ... precision planning application for Transcatheter Aortic-Valve Implantation (TAVI) ... provides interventionalists with pre-procedural, high-precision positioning to treat ... planning application is available as part of Philips ...
(Date:8/21/2014)... CHESTERBROOK, Pa. , Aug. 21, 2014 /PRNewswire/ ... AUXL ), a specialty biopharmaceutical company, today announced ... study of collagenase clostridium histolyticum (or CCH) for ... known as cellulite. In the Phase 2a trial, ... (0.48mg) and high (0.84mg)) showed an improvement in ...
(Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that ... Drug Administration (FDA or Agency) for the AZ-004 New Drug ... the meeting.  In December 2010, Alexza held the End-of-Review meeting ... October 2010.  A CRL is issued by FDA,s Center for ...
... The United States continues to lead the world in its ... , but emerging markets led by China, India and Brazil ... resources and activity overseas, according to a new PwC report ... . While the United States is expected to maintain its ...
Cached Medicine Technology:Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 2Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 3Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 4Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 5Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 6Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwC's Medical Technology Innovation Scorecard 2Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwC's Medical Technology Innovation Scorecard 3Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwC's Medical Technology Innovation Scorecard 4Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwC's Medical Technology Innovation Scorecard 5
(Date:8/21/2014)... 21, 2014 The costs paid by consumers ... rise, according to insurer data. The Quotes Pros company is ... time using its tools at http://quotespros.com . , ... homepage connects with providers offering multiple coverage packages for dental ... to the public are now easier to compare using the ...
(Date:8/21/2014)... August 21, 2014 Today, Zane Benefits, ... on the premium tax credits in 2015. , According ... As part of the Affordable Care Act (ACA), premium ... purchase individual health insurance through the Health Insurance Marketplaces. ... eligibility and the amount of the tax credits, updated ...
(Date:8/21/2014)... the coronary arteries of chronic kidney disease patients may ... to a new study in the Journal of ... Researchers at the Johns Hopkins Bloomberg School of Public ... used measures of subclinical atherosclerosis in predicting the risk ... Approximately 50 percent of all patients with chronic kidney ...
(Date:8/21/2014)... University of Texas MD Anderson Cancer Center today announced ... specialized breast screening at a network of community breast ... in late November, MD Anderson will become the exclusive ... Memorial Hermann,s 10 breast care centers, located in Memorial ... Over time, the network will expand to Memorial Hermann,s ...
(Date:8/21/2014)... is eating better and exercising healthy for people with diabetes, ... a new study finds. The study, led by Mark ... Baptist Medical Center in Winston-Salem, N.C., included more than ... Participants ranged in age from 45 to 76, and ... focused on diet and exercise, or to a standard diabetes ...
Breaking Medicine News(10 mins):Health News:Dental Insurance Now Quoted for Families Online at Insurer Portal 2Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:MD Anderson and Memorial Hermann to operate breast screening network across Houston area 2Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2
... pressure, there were no obvious effects on MKN-45 cells proliferation ... was inhibited and apoptosis improved. It may be that CO2 ... study was performed by a team led by Professor Pei-Wu ... 2008 in the World Journal of Gastroenterology. , There is ...
... ON, May 20 /PRNewswire-FirstCall/ - AlphaRx (OTC ... proprietary drug,delivery technology to develop novel formulations ... an update on recent corporate developments., ... AlphaRx is seeking a listing with the ...
... 21, 2008,Easter Seals Greater Washington-Baltimore Region will honor U.S.,Representative ... for,their efforts on behalf of children and adults with ... at the JW Marriott Hotel,in Washington, D.C, beginning with ... Peterson of WJLA TV will act as Master of ...
... replicate in key organs , , TUESDAY, May 20 (HealthDay News) ... which causes upper respiratory infections and is one of the ... are no drugs specifically approved to treat adenovirus. In part, ... which to test new drugs, something that needs to be ...
... pulmonary disease (COPD) who are in their final years ... pulmonary rehabilitation (PR) as patients who have more years ... lung function, according to new research funded by the ... Thoracic Societys 2008 International Conference in Toronto on Tuesday, ...
... HAE:TSX, MONTREAL, May 20 /PRNewswire-FirstCall/ - ... bio-therapeutics company developing,high-value human plasma-derived protein products ... will present at,Busines$ Meets Finance at the ... at,2:35 p.m., About Busines$ Meets Finance, ...
Cached Medicine News:Health News:AlphaRx Provides Corporate and Development Update 2Health News:Smallpox Drug May Protect Against Common Cold 2Health News:COPD patients benefit more from pulmonary rehab in earlier stages 2Health News:Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre 2
Reference Lab Interface (RLI)© for SRS Software, provides real-time processing of HL7 lab data directly into SRS Freedom Chart ManagerTM, producing an HTML form in the patients chart/tab, whil...
Patient Monitor...
... and a FAM-labeled probe that is designed to ... to detect Flu B. In addition, this ASR ... a separate sample processing control. This ASR requires ... and Texas Red reporter dyes such as the ...
... contains primers and a FAM-labeled probe that ... (RSV). In addition, this ASR contains primers ... sample processing control. This ASR requires an ... Red reporter dyes such as the Cepheid ...
Medicine Products: